Compounds > lutetium
Page last updated: 2024-08-22

lutetium and 4-aminophenylethyl-1,4,7,10-tetraazacyclodecane-n,n',n'',n'''-tetraacetic acid

lutetium has been researched along with 4-aminophenylethyl-1,4,7,10-tetraazacyclodecane-n,n',n'',n'''-tetraacetic acid in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, RC; DePalatis, LR; Frazier, KA; Kotite, NJ1
Cheng, R; Colcher, D; Eggensperger, D; Fordyce, W; Goeckeler, W; Kruper, WJ; Milenic, DE; Schlom, J; Schott, ME; Siler, K1
Brechbiel, MW; Buchsbaum, DJ; Chappell, LL; Khazaeli, MB; Mayo, MS; Rogers, BE1
Brechbiel, MW; Chappell, LL; Dadachova, E; Garmestani, K; Ma, D; Milenic, DE; Schlom, J; Yordanov, A1
Buchsbaum, DJ; Roberson, PL; Rogers, BE; Yokoyama, S1

Other Studies

5 other study(ies) available for lutetium and 4-aminophenylethyl-1,4,7,10-tetraazacyclodecane-n,n',n'',n'''-tetraacetic acid

ArticleYear
Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate.
    Cancer research, 1995, Nov-15, Volume: 55, Issue:22

    Topics: Aniline Compounds; Animals; Antibodies, Monoclonal; Female; Heterocyclic Compounds; Immunoconjugates; Immunoglobulin Fab Fragments; Kidney; Lutetium; Lysine; Mice; Mice, Inbred BALB C; Radioisotopes; Tissue Distribution

1995
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Cancer, 1994, Feb-01, Volume: 73, Issue:3 Suppl

    Topics: Aniline Compounds; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Colonic Neoplasms; Glycoproteins; Heterocyclic Compounds; Humans; Immunotoxins; Iodine Radioisotopes; Lutetium; Metals, Rare Earth; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Samarium; Tissue Distribution; Transplantation, Heterologous; Yttrium Radioisotopes

1994
Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA).
    Bioorganic & medicinal chemistry, 1999, Volume: 7, Issue:11

    Topics: Aniline Compounds; Animals; Chelating Agents; Colorectal Neoplasms; Cross-Linking Reagents; Disease Models, Animal; Heterocyclic Compounds; Humans; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy

1999
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Nuclear medicine and biology, 2002, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Whole-Body Counting; Xenograft Model Antitumor Assays

2002
Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
    Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:2

    Topics: Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Dose-Response Relationship, Radiation; Heterocyclic Compounds; Humans; Lutetium; Mice; Mice, Nude; Models, Biological; Neoplasms, Experimental; Peritoneal Neoplasms; Radioimmunotherapy; Radiotherapy Dosage; Tissue Distribution; Transplantation, Heterologous

2003